• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Interview with Lennert Steukers

2016-01-28News

What is your current role in EPAD?

I’m currently working full time as project manager for Janssen on the IMI-EPAD project. My main role, as member of the EPAD Project Management office and WP5, is to provide overall management to the project including supporting the coordinator in liaising with IMI, work plan & schedule control, stakeholder management, team communication, supporting the Executive Committee and WP leaders in day-to-day management, assurance of timely submission of deliverables and so on. One might say it’s the glue that holds the team together. In addition to that, I’m also actively involved in EPAD’s External Communication activities, governed by WP6.

What did you do prior to joining EPAD?

Prior to joining the EPAD project, I worked in academia at the University of Ghent pursuing a PhD (Microbiology/Veterinary Sciences). My research focused on early events in the pathogenesis of human and animal herpes viruses, more specific on which mechanisms they apply to invade the host. People always ask me why, given my training in Veterinary Medicine, I never became a practitioner. To be honest, although I initially did and still clearly see the many rewarding aspects, I always have been very passionate about the bigger picture of health improvement instead of individual (animal) health and want to be part of driving innovation in the health sector. You can imagine that I’m therefore very pleased to have been given such an opportunity with EPAD.

Tell us a bit about your organisation

At my current assignment at Janssen, I’m part of the Project Management Office across all therapeutic areas specifically dedicated in providing support to the external funding portfolio. Janssen Pharmaceutica N.V., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas and have the main research facilities for Janssen Research & Development in Europe located in Beerse, Belgium, with research focused around the therapeutic areas of neuroscience, oncology, and infectious diseases. The company to which I’m affiliated to is called CMAST BVBA and provides Consultancy, Project Management & Supporting Technology services in the focus process domains of life sciences, strategic collaborations and supply chain in order to enable customers to achieve their strategic goals. CMAST professionals, based in Belgium, Poland and USA, offer sound expertise and a solid track record in Project & Portfolio Management for over 30 IMI projects, 11 FP7 grants and 7 IWT studies related to public health. For me, both companies strive for innovation and quality. It is a pleasure working in such an inspiring environment.

What are your expectations from the EPAD project?

EPAD equals innovation to me. If you think about it, we’re trying to change so many aspects of our way of thinking/doing in AD treatment & management; identification of persons very early in the course of the disease with an increasing accuracy based on knowledge we generate in the project, earlier intervention in this pre-clinical population tested in a proof-of-concept clinical trial environment allowing faster go/no-go decisions in intervention development but also go for a research participant-centred approach by giving persons participating in our studies, their caregivers and families a voice in setting priorities for the project. Sharing, learning from one another in this partnership is crucial. The inspiration/ideation is there, let’s work together on its implementation!

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Edinburgh Dementia Prevention Summer School 2022
2022-06-30
EPAD at AAIC22!
2022-06-30
ADDI NeuroToolKit Data Hackathon
2022-05-17
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
2022-05-09
First national follow-on study to EPAD LCS launches
2022-04-07
The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
2022-03-10
Latest News
  • Edinburgh Dementia Prevention Summer School 2022
    2022-06-30
  • EPAD at AAIC22!
    2022-06-30
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

The @CenDemPrevent Summer School, a 4-day interactive course on #brainhealth, is designed for clinicians, researchers and students. Space is limited, sign up quickly! 🗓️26-29 September 📍Edinburgh For more info, including programme⤵️ ep-ad.org/edinburgh-deme… pic.twitter.com/FSypbvWK4L

reply retweet favorite
12:38 pm · 2022-06-30
Twitter
EPAD
EPAD
@IMI_EPAD

There’s still time to join the @AlzData #NeuroToolKit #Data Hackathon! Registration closes on 24 June! Participants will work with @IMI_EPAD datasets and utilise the tools on the #ADWorkbench. Interested in participating? ➡️alzheimersdata.org/hackathon twitter.com/IMI_EPAD/statu…

reply retweet favorite
7:21 am · 2022-06-22
Twitter
EPAD
EPAD
@IMI_EPAD

Today, colleagues from @AlzData visited @CenDemPrevent to meet with those involved in various programmes including @IMI_EPAD @AD_PREVENT. Many relevant discussions and great catch-up! #BrainHealth #datasharing #collaboration @craig_ritchie68 @samdansobe @GregorySarah @CindyBirck pic.twitter.com/Mr3trKeuoz

reply retweet favorite
2:43 pm · 2022-06-15
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the new @AlzheimerEurope #DementiaInEurope magazine featuring an article on @IMI_EPAD and its collaboration with @AlzData to make our data findable, accessible and reusable. @craig_ritchie68 ⤵️ alzheimer-europe.org/resource… twitter.com/AlzheimerEurop… pic.twitter.com/vLuW3HMLUh

reply retweet favorite
1:09 pm · 2022-06-14
Twitter
EPAD
EPAD
@IMI_EPAD

Registration will close tomorrow! Register now for the free #Brainhealth2022 conference, taking place next week in Edinburgh ⤵️ brainhealth.scot/brainhealth2… twitter.com/IMI_EPAD/statu…

reply retweet favorite
3:05 pm · 2022-06-09
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT